Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454155 · ClinicalTrials.gov registry record · Phase 1
Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
A Phase 1 study, sponsored by Xoma (US).
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00454155 is a Phase 1 study that was terminated before completion, run by Xoma (US). The registered enrollment target is 6 participants.
The verdict
NCT00454155, a Phase 1 study, was terminated before completion, sponsored by Xoma (US).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objectives of this study are as follows: To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine if IV administration of opebacan is associated with changes in biological markers for inflammation To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem Cell Transplantation related complications, including aGvHD
Interventions
- DRUG Opebacan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454155
The ClinicalTrials.gov registry entry for NCT00454155 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Opebacan is the first listed.
NCT00454155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00454155 about?
NCT00454155 is a clinical study titled "Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)". The objectives of this study are as follows: To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic...
What is the current status of trial NCT00454155?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00454155?
The interventions under investigation include: Opebacan (DRUG).
Who is sponsoring clinical trial NCT00454155?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.